SCHEMBL3672650

SCHEMBL3672650

CSc1ccc(C(C)C(=O)O)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 9/20 0.71
AKR1C2 P52895 8/20 0.71
PTGS2 P35354 9/20 0.57
PTGS1 P23219 7/20 0.53
CYP2C9 P11712 4/20 0.53
LMNA P02545 3/20 0.53
CXCR1 P25024 2/20 0.53
CXCR2 P25025 2/20 0.53
ALB P02768 1/20 0.53
ESR1 P03372 1/20 0.53
ALOX5 P09917 1/20 0.53
RARB P10826 1/20 0.53
ADRB3 P13945 1/20 0.53
NFKB1 P19838 1/20 0.53
HTR2A P28223 1/20 0.53
NR1I3 Q14994 1/20 0.53
SLC22A6 Q4U2R8 1/20 0.53
CXCL8 P10145 1/20 0.53
TSHR P16473 1/20 0.53
BLM P54132 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8834913 0.85 AKR1C3 (0.53) AKR1C3AKR1C2PTGS2ACACBFPR2
SCHEMBL59197 0.84 PTGS2 (0.74) AKR1C3AKR1C2PTGS2PTGS1CYP2C9
SCHEMBL29960739 0.83 AKR1C3 (1.00) AKR1C3AKR1C2PTGS2PTGS1SLC22A6
SCHEMBL20541007 0.83 AKR1C3 (1.00) AKR1C3AKR1C2PTGS2PTGS1SLC22A6
SCHEMBL18770086 0.83 AKR1C3 (1.00) AKR1C3AKR1C2PTGS2PTGS1SLC22A6
SCHEMBL11458833 0.83 AKR1C3 (1.00) AKR1C3AKR1C2PTGS2PTGS1SLC22A6
Ammonia Solution, Strong SCHEMBL11728310 0.82 AKR1C3 (0.97) AKR1C3AKR1C2PTGS2PTGS1SLC22A6
SCHEMBL5677024 0.82 EPHX1 (0.55) AKR1C3AKR1C2ACACBALDH1A1
SCHEMBL9493972 0.81 SRC (0.54) AKR1C3AKR1C2LMNAACACBFPR2
SCHEMBL9235111 0.80 PTGS2 (0.63) AKR1C3AKR1C2PTGS2PTGS1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7812038-B2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS, INC. (US) 2010-10-12 US disclosed
US-20060276476-A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors BIEDIGER RONALD J 2006-12-07 US disclosed
US-6972296-B2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS INC. (US) 2005-12-06 US disclosed
US-4245099-A ANTIINFLAMMATORY, ANALGESIC, DIURETIC, ANTIPYRETIC AND HYPOTENSIVE AGENTS ONO PHARMACEUTICAL CO., LTD. (JP) 1981-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276476-A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors VCAM1, ICAM1, ITGA1 AKR1C3 809/4885AKR1C2 844/4885PTGS2 3523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.